Cognitive profiles on the severe Impairment Battery are similar in Alzheimer disease and Down syndrome with dementia

Alzheimer Disease and Associated Disorders

Volumn 30, Issue 3, 2016, Pages 251-257

  Dick, Malcolm B ^a   Doran, Eric ^b   Phelan, Michael ^c   Lott, Ira T ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Pediatrics ^*  (United States)

^c School of Medicine   (United States)

^d 5226 Donald Bren Hall   (United States)

Author keywords

Alzheimer disease; Bristol Activities of Daily Living Scale; Cognitive profile; Down syndrome; Severe Impairment Battery

Indexed keywords

ACTIVITY OF DAILY LIVING ASSESSMENT; ADULT; AFRICAN AMERICAN; AGE; AGED; ALZHEIMER DISEASE; AMERICAN INDIAN; ARTICLE; ASIAN; ATTENTION; BRISTOL ACTIVITIES DAILY LIVING SCALE; CAUCASIAN; COGNITION ASSESSMENT; COMPREHENSION; CONTROLLED STUDY; DEPRESSION; DEPTH PERCEPTION; DISEASE SEVERITY; DOWN SYNDROME; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; FUNCTIONAL DISEASE; HUMAN; INTELLIGENCE; LANGUAGE ABILITY; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL CAPACITY; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; ORIENTATION; PACIFIC ISLANDER; PHYSICAL CAPACITY; PRAXIS; PRIORITY JOURNAL; SEVERE IMPAIRMENT BATTERY; SOCIAL INTERACTION; COGNITIVE DEFECT; COMPARATIVE STUDY; COMPLICATION; DAILY LIFE ACTIVITY; MIDDLE AGED; PSYCHOLOGY; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; COGNITION DISORDERS; DOWN SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RISK FACTORS;

EID: 84951320683     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0000000000000132     Document Type: Article

References (35)

1. Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol. 2010;9:623-633.
2. Nieuwenhuis-Mark RE. Diagnosing Alzheimer's dementia in Down syndrome: problems and possible solutions. Res Dev Disabil. 2009;30:827-838.
3. Zigman WB, Devenny DA, Krinsky-McHale SJ, et al. Alzheimer's disease in adults with Down syndrome. Int Rev Res Ment retard. 2008;36:103-145.
4. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614-629.
5. Ball SL, Holland AJ, Treppner P, et al. Executive dysfunction and its association with personality and behavioral changes in the development of Alzheimer's disease in adults with Down syndrome and mild to moderate learning disabilities. Br J Clin Psychol. 2008;47:1-29.
6. Lott IT, Head E. Down syndrome and Alzheimer's disease: a link between development and aging. Ment Retard Dev Disabil Res Rev. 2001;7:172-178.
7. Ball SL, Holland AJ, Hon J, et al. Personality and behaviour changes mark the early stages of Alzheimer's disease in adults with Down syndrome: findings from a prospective populationbased study. Int J Geriatr Psychiatry. 2006;21:661-673.
8. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
9. Rosen WG, Mohs RC, Davis KL, et al. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
10. Deb S, Braganza J. Comparison of rating scales for the diagnosis of dementia in adults with Down's syndrome. J Intellect Disabil Res. 1999;43:400-407.
11. Ball SL, Holland AJ, Huppert FA, et al. The modified CAMDEX informant interview is a valid and reliable tool for use in the diagnosis of dementia in adults with Down's syndrome. J Intellect Disabil Res. 2004;48:611-620.
12. Sparrow SS, Balla DA, Cicchetti DV. Vineland Adaptive Behavior Scales: Interview Edition-Survey Form. Circle Pines, MN: American Guidance Service; 1984.
13. Dalton A, Fedor B. DYSPRAXIA Scale for Adults With Down Syndrome. Staten Island, NY: NYS Institute for Basic Research in Developmental Disabilities; 1997.
14. Haxby JV. Neuropsychological evaluation of adults with Down syndrome: patterns of selective impairment in nondemented old adults. J Ment Defic Res. 1989;33:193-210.
15. Saxton J, McGonigle KL, Swihart AA, et al. The Severe Impairment Battery. Suffolk, England: Thames Valley Test Company; 1993.
16. Saxton J, McGonigle-Gibson K, Swihart A, et al. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. Psych Assess. 1990;2:298-303.
17. De Jonghe J F M, Wetzels RB, Mulders A, et al. Validity of the severe impairment battery short version. J Neurol Neurosurg Psychiatry. 2009;80:954-959.
18. Schmitt FA, Saxton J, Ferris SH, et al. Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study. In J Clin Pract. 2013;67:1050-1056.
19. Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl):51-65.
20. Bucks R, Ashworth D, Wilcock G, et al. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing. 1996;25:113-120.
21. Ferris S, Ihl R, Robert P, et al. Severe Impairment Battery Language Scale: a language-assessment tool for Alzheimer's disease patients. Alzheimers Dement. 2009;5:375-379.
22. Ferris S, Mackell J, Bai Z, et al. Effect of donepezil 23mg/day on language function in patients with moderate-to-severe Alzheimer's disease (AD): subgroup analysis of United States (US)-based patients. Alzheimers Dement. 2012;8(suppl):591-592.
23. Ferris S, Schmitt FA, Saxton J, et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimer Res Ther. 2011;3:22.
24. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and human Services task Force on Alzheimer's disease. Neurology. 1984;34:939-944.
25. Teng E, Ringman JM, Ross LK, et al. Diagnosing depression in Alzheimer's disease with the National Institute of Mental Health provisional criteria. Am J Geriatr Psychiatry. 2008;16:469-477.
26. Pfeffer R, Kurosaki T, Harrah C, et al. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323-329.
27. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
28. Evenhuis HM. Evaluation of a screening instrument for dementia in aging mentally retarded persons. J Intellect Disabil Res. 1992;36:337-347.
29. Määttä T, Trevo-Määttä T, Taanila A, et al. Mental health, behavior and intellectual abilities of people with Down syndrome. Downs Syndr Res Pract. 2006;11:37-43.
30. Venables WN, Ripley BD. Modern Applied Statistics With S, 4th ed. New York: Springer; 2002.
31. Core Team R. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2014. Available at: http://www. R-project.org/.
32. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer's disease. Neurology. 2007;69:459-469.
33. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367:1057-1065.
34. Reisberg B, Doody R, Stoffler A, et al. Memantine Study Group: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.
35. Zakzanis KK, Leach L, Kaplan E. Neuropsychological Differential Diagnosis. Lisse, The Netherlands: Swets & Zeitlinger; 1999.